ScreenerHero

GOVXGeoVax Labs, Inc.

NAS · US · Healthcare · Biotechnology · geovax.com
0.6456USD+8.56%Mkt Cap: 3.36M $P/E: —

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.36M $
Enterprise Value1.62M $
Revenue (TTM)0 $
Gross Profit-15.05M $
Net Income (TTM)-21.46M $
Revenue/Share0.0000 USD
Last Price0.6456 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.70
PEG—
EV/EBITDA-0.08
EV/Revenue—
P/SInfinity
P/B2.52
EPS (TTM)-5.67
EPS (Forward)-0.86
52W Range
0.59000% of range20.00
52W High20.00 USD
52W Low0.5900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-862.34%
ROE-561.15%
ROA-338.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.47M $
CapEx (TTM)27.61K $
FCF Margin—
FCF Yield-321.65%
Net Debt-2.82M $
Net Debt/EBITDA0.14
Balance Sheet
Debt/Equity0.22
Current Ratio1.54
Quick Ratio1.16
Book Value/Sh0.2390 USD
Cash/Share0.4270 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 25, 2020
Splits
Last Split1:25
Split DateJan 12, 2026
Analyst Consensus
Rating—
Target (Mean)10.00 USD
Upside (mean)+1448.9%
Target Range10.00 USD – 10.00 USD
# Analysts2
Ownership
Shares Out.5.21M
Float7.37M
Insiders3.20%
Institutions12.06%
Short Interest
Short Ratio0.2d
Short % Float1.10%
Short % Out.1.10%
Shares Short57.28K
Short (prev mo.)62.85K
Technical
SMA 500.9804 (-34.1%)
SMA 2003.245 (-80.1%)
Beta3.66
S&P 52W Chg18.16%
Avg Vol (30d)632.74K
Avg Vol (10d)1.49M
Technical Indicators
RSI (14)34.7
MACD-0.1080
MACD Signal-0.1191
MACD Hist.+0.0111
BB Upper0.8269 USD
BB Middle0.7220 USD
BB Lower0.6171 USD
BB Width29.06%
ATR (14)0.0970 USD
Vol Ratio (20d)0.81x